Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Small molecule compounds targeting multiple kinases involved in neoangiogenesis have shown survival benefits in patients with unresectable hepatocellular carcinoma (HCC). Nonetheless, despite the beneficial effects of multikinase inhibitors (MKIs), a lack of boosting adjuvant limits their objective...

Description complète

Détails bibliographiques

Auteurs principaux:	Ke Wang, Pei-Yin Liao, Wei-Chun Chang, Cian-Ru Yang, Yu-Ting Su, Ping-Ching Wu, Yang-Chang Wu, Yao-Ching Hung, Najim Akhtar, Hsueh-Chou Lai, Wen-Lung Ma
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2024-01-01
Collection:	Frontiers in Pharmacology
Sujets:	hepatocellular carcinoma LDC linoleate pazopanib LAPC
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1281067/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!